Cary, N.C. – November 17, 2015 – Industry Standard Research (ISR) is announcing the availability of a new report titled Clinical Development Outsourcing Models (2nd edition). This report reveals sponsors’ satisfaction and preferences with seven different outsourcing models, their reasons for model selection, and how each model is used. It also provides insight into how often each model is used and predictions for future trends in this space.
“Most pharma companies no longer outsource simply because they have to. Most now recognize value in the use of contract organizations,” said Andrew Schafer, President of ISR. “The real trick for a head of R&D is identifying which model is best given the particular pharma company’s culture, infrastructure for clinical trial management, infrastructure for CRO management, depth of pipeline, and a host of other factors.
“Another key takeaway,” Schafer continues, “is that these data also highlight key benefits of and top reasons for using each model.” Outsourcing models examined in this report include: Preferred Provider, In-Sourcing, Fee-for-Service, Functional Service Provider (FSP), Compound or Program-based, Hybrid Full Service and FSP, and Sole-Source. Of those models, In-Sourcing and Functional Service Provider performed better in meeting expectation compared to other models. The top reasons respondents chose these models include: Increased resource flexibility, Access to additional core resources, and Access to specific skills/expertise not present within the organization.
The data in this report were collected from 107 respondents in both pharma and biotech companies, each respondent having responsibility for outsourcing clinical trials and highly knowledgeable of their organization’s clinical development outsourcing model.
Pharma buyers can use this report to navigate the benefits and drawbacks of available outsourcing models by examining what is working and not working for other companies and why. Service providers are encouraged to use these data to plan for the rise and decline of these models, identify drivers of success, and anticipate customers’ needs accordingly.
For more information about ISR’s Clinical Development Outsourcing Models (2nd edition) report, please visit the report page.
